ALG Advises Endo, Inc. on its Proposed US$3.7bn Business Combination with Mallinckrodt
March, 2025 - Ireland
ALG is pleased to be advising Endo. on its proposed business combination with Mallinckrodt Pharmaceuticals, which will create a global, scaled and diversified pharmaceuticals leader with a combined pro forma enterprise value of $6.7bn. Endo and Mallinckrodt plan to combine Mallinckrodt’s generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction and intend to separate that business from the combined company at a later date.
Alan Casey, Head of A&L Goodbody’s Corporate Department, commented: “We are delighted to be advising our longstanding client Endo on this transaction. This combination has the potential to be transformational and to unlock the full potential of both companies. This deal underlines our team’s expertise in high value and innovative deals in the international M&A market.”
The ALG Corporate M&A team was led by Alan Casey together with partner, Deirdre Geraghty, and senior associate, Conor Maginn, alongside a wider team including partners Amelia O'Beirne (Tax), Peter Murray (Finance) and Alan McCarthy (Anti-Trust/Regulatory).
